Free Trial

Viridian Therapeutics (VRDN) News Today

$12.11
-0.05 (-0.41%)
(As of 05/24/2024 ET)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have given a
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5%
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5%
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5%
Viridian Therapeutics (VRDN) Gets a Buy from Stifel Nicolaus
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
FY2028 EPS Estimates for Viridian Therapeutics, Inc. Reduced by Analyst (NASDAQ:VRDN)
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for Viridian Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the compan
Viridian Therapeutics (NASDAQ:VRDN) Given New $27.00 Price Target at HC Wainwright
HC Wainwright lowered their target price on shares of Viridian Therapeutics from $37.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday.
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down on Analyst Downgrade
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down Following Analyst Downgrade
Viridian Therapeutics (NASDAQ:VRDN) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.28. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The firm's revenue was down 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.61) EPS.
Viridian Therapeutics (NASDAQ:VRDN) Stock Rating Lowered by LADENBURG THALM/SH SH
LADENBURG THALM/SH SH downgraded Viridian Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday.
Viridian Therapeutics (NASDAQ:VRDN) Rating Reiterated by Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Viridian Therapeutics in a research note on Thursday.
Viridian Therapeutics (VRDN) Set to Announce Quarterly Earnings on Wednesday
Viridian Therapeutics (NASDAQ:VRDN) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591036)
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 6.2%
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 6.2%
Knights of Columbus Asset Advisors LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Knights of Columbus Asset Advisors LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 420.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 153,949 shares of the compan
Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume
Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume
Viridian Therapeutics (NASDAQ: VRDN)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. lessened its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,448,015 shares of the company's stock
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from Brokerages
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12-month target price among an
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLC
SG Americas Securities LLC decreased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 60.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,588 shares of the company's stoc
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% Following Analyst Downgrade
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% on Analyst Downgrade
B. Riley Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $25.00
B. Riley reduced their price objective on Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday.
Unveiling 4 Analyst Insights On Viridian Therapeutics
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at Needham & Company LLC
Needham & Company LLC restated a "buy" rating and set a $30.00 price target on shares of Viridian Therapeutics in a research note on Wednesday.
VRDN Sep 2024 20.000 put
VRDN Apr 2024 20.000 put
Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

Nvidia’s Quiet $1 Trillion Pivot (Ad)

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.

VRDN Media Mentions By Week

VRDN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VRDN
News Sentiment

0.64

0.50

Average
Medical
News Sentiment

VRDN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VRDN Articles
This Week

4

3

VRDN Articles
Average Week

Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:VRDN) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners